仿生设备市场：竞争分析、最新发展、企业策略、永续性基准、产品发布、主要参与者及收入预测

全球仿生设备市场规模及预测（2025-2033）

全球仿生设备市场预计将从2025年的62.2亿美元成长到2033年的约119亿美元，2025年至2033年的复合年增长率（CAGR）为8.45%。推动这一成长的关键因素包括穿戴式机器人、义肢和矫形器的进步、慢性疾病和残疾的增加，以及对个人化、非侵入性医疗服务日益增长的需求。此外，人工智慧和新材料的开发，以及医疗保健支出的成长，预计也将使患者受益，并推动设备性能的提升。

仿生设备是一种旨在模仿或增强活体肢体或器官功能的先进技术。 许多此类技术融合了机器人技术、感测器和人工智慧，旨在恢復或改善残疾人或肢体残缺者的行动能力和功能。典型的例子包括模拟自然运动的义肢、辅助听力的人工耳蜗，以及辅助行走的高级外骨骼。

由于人们意识的提高和技术的快速发展，仿生设备在全球范围内日益普及。随着医学研究的进展，这些设备不断改进，变得更加精密、轻巧、易用。这种更高的可及性使更多人能够受益于仿生解决方案。此外，全球人口老化和需要截肢的疾病数量不断增加，也进一步推动了仿生技术在市场上的扩张。

美国、德国和日本在仿生技术的研发和应用方面处于领先地位，对復健和生活品质产生了革命性的影响。随着社会拥抱医疗保健领域的创新，仿生科技的未来充满希望，为世界各地的许多人带来了希望。

全球仿生设备市场最新动态

美敦力

2025年2月，美敦力宣布其全球首个用于治疗巴金森氏症的闭环式aDBS系统获得美国FDA批准。该设备可根据个别脑部活动即时自动调节刺激强度，标誌着运动障碍治疗领域首个市场级突破。该技术也被 "时代" 杂誌评为 "2025年最佳发明" 之一。

威廉·德曼控股公司

德曼宣布以7亿欧元收购德国助听器零售连锁企业KIND集团，预计2025年下半年完成交易。此次收购是德曼巩固其在德国助听器市场领先地位的一项重大战略举措，并将使其在德国、瑞士、奥地利、卢森堡和新加坡新增约600家诊所。

本报告对仿生设备市场进行了研究，并分析了17家主要公司的最新发展、策略、永续性、产品和收入。

目录

第一章：仿生设备市场

• 历史趋势
• 预测分析

第二章：市占率分析 - 仿生设备市场

第三章：雅培实验室

• 概述
  • 公司历史与使命
  • 商业模式与营运
  • 员工队伍
• 主要人员
  • 执行管理团队
  • 业务管理团队
  • 部门领导
  • 董事会组成
• 近期发展与策略
  • 併购收购
  • 合作伙伴关係
  • 投资
• 永续性分析
  • 再生能源应用
  • 节能基础设施
  • 永续包装材料的使用
  • 用水和节水策略
  • 废弃物管理与循环经济举措
• 产品分析
  • 产品概况
  • 品质标准
  • 产品线
  • 产品基准分析
• 策略评估：SWOT 分析
• 收入分析

以上资讯适用于以下所有公司。

1. 雅培实验室

2. Abiomed

3. 爱德华生命科学公司

4. Rewalk Robotics Ltd.

5. Boston Scientific Corp.

6. Baxter International Inc.

7. Cochlear Ltd.

8. Medtronic Plc.

9. William Demant Holdings A/S

10. EKSO Bionics Holdings Inc.

11. Ottobock SE & Co. KGaA

12. Sonova Holding AG

13. Bionik Laboratories Corp.

14. Pixium Vision SA

15. Open Bionics Ltd.

16. Cyber​​dyne 公司

17. Myomo 公司

Global Bionic Devices Market Size and Forecast 2025-2033

The Bionic Devices Market is anticipated to be worth about US$ 11.90 billion by 2033, from US$ 6.22 billion in 2025, growing at a CAGR of 8.45% during 2025-2033. Key factors driving this expansion include technological advances in wearable robotics and prosthetics, rising chronic illnesses and disabilities, and an increasing demand for personalized and non-invasive medical treatments. Additionally, emerging artificial intelligence and material development and increased health expenditure are further expected to benefit patients and enhance devices' performance.

Bionic devices are the advanced technologies engineered to emulate or enhance the functions of biological limbs or organs. Many of them involve the integration of robotics, sensors, and artificial intelligence to restore or improve mobility and functionality in individuals with disabilities or limb loss. Common examples include prosthetic limbs that can emulate natural movement, cochlear implants for hearing, and even advanced exoskeletons that help individuals walk.

Bionic devices have surged in popularity across the globe due to increased awareness and rapid advancement in technology. As medical research evolves, such devices are continuously being manufactured to be more sophisticated, lighter in weight, and easier to use. With this rise in accessibility, a larger population is able to benefit from bionic solutions. In addition, an aging global population and a rise in conditions that require amputation have driven further growth into the marketplace.

The United States, Germany, and Japan have been in the lead of developments and deployments of bionic technologies, and subsequently, transformative impacts on rehabilitation and quality of life are being felt. As society embraces innovation in health, the future for bionics is promising, with hope being given to many around the world.

Top 5 Companies in the Global Bionic Devices Market by 2033

1. Abbott Laboratories

Headquarters: United States of America

Founded: 1888

Abbott Laboratories is one of the leading medical device and healthcare companies that discovers, develops, manufactures, and sells diversified products in the world market. The business portfolio of Abbott consists of gastroenterology and women's health, cardiovascular and metabolic health, pain management, central nervous system disorders, and many more. It also covers respiratory drugs and vaccines, biosimilars, core laboratory systems, and transfusion medicine technologies along with point-of-care systems. Its portfolio also comprises rapid diagnostic lateral flow tests, informatics and automation solutions, nutritional products, and rhythm management, electrophysiology, and heart failure-related devices. Its product portfolio encompasses a wide range of vascular and structural heart needs as well as neuromodulation therapies. Abbott undertakes to market its products primarily through wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and retail buyers, among independent retailers. The company markets its products in North America, Latin America, the Middle East, Europe, the Asia-Pacific, and Africa.

2. Abiomed

Headquarters: United States of America

Founded:1981

Abiomed Inc is a medical device company. The company is involved in the design and development of heart pump technologies. The Impella family gives patients with severe coronary artery disease and heart failure temporary hemodynamic support. Its product pipeline includes Impella CP for high-risk PCI procedures and cardiogenic shock, and Impella 5.5, which provides full cardiac support over long durations. Impella RP supports patients with right heart failure. Abiomed offers the Breethe OXY-1 System, a compact cardiopulmonary support device featuring an integrated oxygenator that oxygenates and pumps blood while enabling patient mobility. The company also offers Impella Connect, a cloud-based platform that allows healthcare teams to remotely monitor patient status.

3. Edward Lifesciences Corp.

Headquarters: United States of America

Founded: 1958

Edwards Lifesciences Corp (Edwards Lifesciences) is a medical technology company. It develops, manufactures and markets devices for structural heart disease, critical care and surgical monitoring. The company's products comprise surgical valve repair devices, surgical valve replacement, hemodynamic monitoring devices, transcatheter heart valves, pressure monitoring devices, and related instruments and accessories. Its products find application for various therapies such as transcatheter aortic valve replacement (TAVR), blood conservation, infection control, enhanced surgical recovery, and for the management of clotting, hypotension and sepsis. The company markets products through a direct sales force and a network of independent distributors in North America, Europe and Asia-Pacific

4. Rewalk Robotics Ltd.

Headquarters: Israel

Founded: 2001

Lifeward Inc (Lifeward), formerly ReWalk Robotics Ltd, is a medical device company that designs, develops and commercializes exoskeletons. The company offers walk restoration devices for people with lower limb disabilities to stand and walk once again. Its products include rewalk personal systems and ReWalk rehabilitation. Lifeward's rewalk personal system is a battery-powered system that controls movement using subtle changes in the center of gravity. The company's Rewalk Rehabilitation is designed for clinics to provide exercise and therapy for patients. It serves medical equipment, rehabilitation centers, and healthcare sectors. The company operates in the US, Germany and Israel. Lifeward is headquartered in Yokne'am Illit, Israel.

5. Boston Scientific Corp.

Headquarters: United States of America

Founded: 1979

Boston Scientific Corp (Boston Scientific) is a medical technology company that develops, manufactures, and commercializes devices for a range of interventional medical specialties. The company offers products in the areas of electrophysiology, gastroenterology, gastrointestinal surgery, female pelvic medicine, gynecology, interventional cardiology, interventional radiology, neurological surgery, orthopedic surgery, pain medicine, pulmonology, urology, and vascular surgery. Boston Scientific serves hospitals, clinics, outpatient facilities, and medical offices across the world. The company has manufacturing facilities in the US, Ireland, Costa Rica, Brazil, Malaysia, and Puerto Rico. It sells products directly and through a network of distributors and dealers in Europe, the Middle East, Africa, Asia Pacific, and the Americas.

Product Launches in the Bionic Devices Market

Pixium Vision SA

March 2023 | Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX) is a bioelectronics company that develops innovative bionic vision systems intended to enable patients who have lost their sight to lead more independent lives. Today, the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its Prima System. This system is a photovoltaic substitute for photoreceptors, providing the ability to use simultaneously a central prosthetic and peripheral natural vision in patients with atrophic dry age-related macular degeneration (AMD), aiming to partially restore their vision.

Cochlear Limited

July 2025, Cochlear Limited, the global leader in implantable hearing solutions, has announced the approval of the Cochlear(TM) Nucleus(R) Nexa(TM) System by the U.S. Food and Drug Administration (FDA). This system is the world's first and only smart cochlear implant. Until now, recipients of cochlear implants have been limited to accessing new technology through the external component, known as the sound processor. Typically, to fully benefit from new technologies, users would need to obtain a new sound processor. The Nexa System introduces upgradeable implant firmware, allowing Cochlear recipients to access future innovations through both their implant and sound processor for the first time. This new pathway for firmware updates will enhance sound processor upgrades, ensuring recipients can experience optimal hearing and have greater access to new advancements over time.

SWOT Analysis of Company in the Bionic Devices Market

EKSO Bionics Holdings Inc.

Strength - Technological Leadership in Wearable Exoskeleton Innovation

The greatest strength of Ekso Bionics Holdings Inc. in the field of bionic devices is its pioneering technological resource and leading position in the development of sophisticated wearable exoskeletons for medical, industrial, and defense applications. Its deep R&D capabilities have empowered the development of high-performance, human-augmenting systems like EksoNR and EksoVest, enhancing mobility, rehabilitation, and physical fortitude. With its strong foundation in robotics, biomechanics, and human-machine integration, Ekso Bionics offers precise, adaptive solutions in support of stroke and spinal cord injury rehabilitation, while improving workplace safety and productivity. Strategic partnerships with leading healthcare institutions, rehabilitation centers, and industrial enterprises further strengthen Ekso's innovation ecosystem and market credibility. With a portfolio built on patented technologies and clinical validation, Ekso Bionics sustains competitiveness, positioned as a trusted leader in progressing human mobility and functional recovery by intelligent bionic engineering.

Ottobock SE & Co. KGaA

Strength: Global Leadership in Prosthetics and Human Mobility Solutions

The key strength of Ottobock SE & Co. KGaA in the bionic devices market is its century-long experience in leading innovation in prosthetics and orthotics, combining medical know-how with the most up-to-date mechatronics and biotechnology. Its strong R&D foundation has come up with revolutionary products such as the C-Leg, Genium X3, and Michelangelo Hand that set global standards for functional precision and user comfort. Ottobock's intimate knowledge in human biomechanics and rehabilitation medicine forms the basis for developing outstandingly adaptive bionic systems that return natural movement and independence to users. Extensive global distribution with clinical partnerships and personalized fitting services increases accessibility and trust in its brand. Moreover, Ottobock's focus on integrating more digital technologies, such as AI-based motion analysis and smart prosthetic control elements, cements its leading role in patient-oriented innovation. This combination of technological excellence, global reach, and clinical expertise makes Ottobock a benchmark in the evolving bionic mobility market.

Recent Development in Global Bionic Devices Market

Medtronic Plc

In February of 2025, Medtronic announced the U.S. FDA approval of the world's first closed-loop aDBS system for Parkinson's disease. This device automatically adjusts stimulation in real-time based on individual brain activity-a first-to-market advance in the treatment of movement disorders. The technology was also named one of TIME's Best Inventions of 2025.

William Demant Holdings A/S

Demant announced and expects to complete the acquisition of the German hearing care retail chain KIND Group for €700 million in the second half of 2025. This acquisition is a major strategic move to secure a leading position in the German hearing care market, adding around 600 clinics in Germany, Switzerland, Austria, Luxembourg, and Singapore.

Sustainability Goals in Global Bionic Devices Market

Sonova Holding AG

Sonova Holding AG's sustainability vision aims at long-term value creation by combining innovative hearing solutions with environmental stewardship and social responsibility. This includes pursuing carbon-neutral operations through further energy efficiency optimization, increased renewable energy sources, and decreased GHG emissions at productions and within supply chains. Sonova advances sustainable product design, focusing on durability, recyclability, and minimization of waste across the life cycle of products. Socially, it fosters inclusion through international hearing health programs, striving to give people in need access to hearing care worldwide through its Hear the World Foundation. Employee engagement, diversity, and ethical governance form key pillars of the company's sustainability vision. Through integrating environmental, social, and economic goals, Sonova seeks to provide sustainable innovation that will improve the quality of life for millions of people while preserving the planet: making sure better hearing goes together with a better future.

Bionik Laboratories Corp.

Bionik Laboratories Corp.'s sustainability objective is focused on enhancing human mobility through robotics and assistive technology, coupled with a commitment to environmental responsibility, ethical business operations, and social accountability. In that regard, the company pursues creating long-lasting, efficient rehabilitation and mobility devices that are waste-efficient and conserve natural resources throughout their life cycle. Considerations of sustainability within product design help Bionik develop long-lasting robotic systems that reduce hospital maintenance costs and minimize environmental impact. The firm also places emphasis on responsible sourcing, lean manufacturing, and ethics in labor practices among its suppliers. Social sustainability is one of the corners of its operation, through which Bionik seeks to improve the quality of lives of patients recovering from neurological disorders with accessible, patient-centered solutions. It fosters an inclusive culture internally that values innovation, employee well-being, and diversity. All told, the vision of Bionik reflects a path toward aligning technological progress with global strides for a healthy, fair, and ecologically sensitive future.

Market Segmentation

Bionic Devices Market

• Historical Trends
• Forecast Analysis

Market Share Analysis - Bionic Devices Market

Abbott Laboratories

Overview

• Company History and Mission
• Business Model and Operations
• Workforce

Key Persons

• Executive Leadership
• Operational Management
• Division Leaders
• Board Composition

Recent Development & Strategies

• Mergers & Acquisitions
• Partnerships
• Investments

Sustainability Analysis

• Renewable Energy Adoption
• Energy-Efficient Infrastructure
• Use of Sustainable Packaging Materials
• Water Usage and Conservation Strategies
• Waste Management and Circular Economy Initiatives

Product Analysis

• Product Profile
• Quality Standards
• Product Pipeline
• Product Benchmarking

Strategic Assessment: SWOT Analysis

• Strengths
• Weaknesses
• Opportunities
• Threats

Revenue Analysis

The above information will be available for all the following companies:

• 1. Abbott Laboratories
• 2. Abiomed
• 3. Edward Lifesciences Corp.
• 4. Rewalk Robotics Ltd.
• 5. Boston Scientific Corp.
• 6. Baxter International Inc.
• 7. Cochlear Ltd.
• 8. Medtronic Plc,
• 9. William Demant Holdings A/S
• 10. EKSO Bionics Holdings Inc.
• 11. Ottobock SE & Co. KGaA
• 12. Sonova Holding AG
• 13. Bionik Laboratories Corp.
• 14. Pixium Vision SA
• 15. Open Bionics Ltd.
• 16. Cyberdyne Inc.
• 17. Myomo, Inc.

Table of Contents

1. Bionic Devices Market

• 1.1 Historical Trends
• 1.2 Forecast Analysis

2. Market Share Analysis - Bionic Devices Market

3. Abbott Laboratories

• 3.1 Overview
  • 3.1.1 Company History and Mission
  • 3.1.2 Business Model and Operations
  • 3.1.3 Workforce
• 3.2 Key Persons
  • 3.2.1 Executive Leadership
  • 3.2.2 Operational Management
  • 3.2.3 Division Leaders
  • 3.2.4 Board Composition
• 3.3 Recent Development & Strategies
  • 3.3.1 Mergers & Acquisitions
  • 3.3.2 Partnerships
  • 3.3.3 Investments
• 3.4 Sustainability Analysis
  • 3.4.1 Renewable Energy Adoption
  • 3.4.2 Energy-Efficient Infrastructure
  • 3.4.3 Use of Sustainable Packaging Materials
  • 3.4.4 Water Usage and Conservation Strategies
  • 3.4.5 Waste Management and Circular Economy Initiatives
• 3.5 Product Analysis
  • 3.5.1 Product Profile
  • 3.5.2 Quality Standards
  • 3.5.3 Product Pipeline
  • 3.5.4 Product Benchmarking
• 3.6 Strategic Assessment: SWOT Analysis
  • 3.6.1 Strengths
  • 3.6.2 Weaknesses
  • 3.6.3 Opportunities
  • 3.6.4 Threats
• 3.7 Revenue Analysis

The above information will be available for all the following companies:

1. Abbott Laboratories

2. Abiomed

3. Edward Lifesciences Corp.

4. Rewalk Robotics Ltd.

5. Boston Scientific Corp.

6. Baxter International Inc.

7. Cochlear Ltd.

8. Medtronic Plc,

9. William Demant Holdings A/S

10. EKSO Bionics Holdings Inc.

11. Ottobock SE & Co. KGaA

12. Sonova Holding AG

13. Bionik Laboratories Corp.

14. Pixium Vision SA

15. Open Bionics Ltd.

16. Cyberdyne Inc.

17. Myomo, Inc.